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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S2848 weeks post treatment. Blood samples were screened to detect the
replication competent retrovirus (RCR), retrovirally transduced cells
and TGF-b1 protein starting from 2 weeks up to 6 months post
treatment. Safety measures including physical exams, complete blood
count, and serum chemistry were included up to 6 months post
treatment.
Results: TG-C signiﬁcantly improved IKDC, WOMAC, and 100 mm VAS
scores. Low and high doses of TG-C treatment showed signiﬁcant
improvement in total IKDC score by 33% (from 44.9  7.8 to 59.93 
10.5, p<0.001) and by 25% (from 49.9 2  9.5 to 62.48  9.7, p<0.001),
respectively, at 6 month post treatment. Low and high doses of TG-C
treatment showed signiﬁcant improvement in WOMAC scores by 45%
(from 31.92  8.4 to 17.43  8.2, p<0.001) and by 41% (from 30.00  9.5
to 17.79  9.7), respectively, at 6 month post treatment. Low and high
doses of TG-C treatment also improved 100mmVAS scores from by 47%
(51.07  13.4 to 26.50  14) and by 45% (from 50.77  13.3 to 28.14
11.2), respectively, at 6 month post treatment. No SAEs were shown in
the treatment groups.
Conclusions: The current phase IIa study indicated that TG-C improved
three evaluation criteria for pain, sports activities, and quality of daily
life in patients with osteoarthritis without showing SAEs.
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THE INTENSIVE DIET AND EXERCISE FOR ARTHRITIS TRIAL (IDEA):
EFFECTS ON KNEE JOINT LOADING AND INFLAMMATION
S.P. Messier 1, P. DeVita 2, B.J. Nicklas 3, D. Beavers 3, S. Mihalko 1,
G.D. Miller 1, M. Lyles 3, D.J. Hunter 4, F. Eckstein 5, C. Legault 3,
J.D. Williamson 3, J.J. Carr 3, R.F. Loeser 3. 1Wake Forest Univ., Winston-
Salem, NC, USA; 2 East Carolina Univ., Greenville, NC, USA; 3Wake Forest
Univ. Sch. of Med., Winston-Salem, NC, USA; 4Univ. of Sydney, Sydney,
Australia; 5 Paracelsus Med. Univ., Salzburg, Austria
Purpose: Overweight and obesity is the most modiﬁable risk factor for
symptomatic knee osteoarthritis (OA), and dietary induced weight loss
combined with exercise is potentially the best non-pharmacologic
treatment. We report the mechanistic primary outcomes of a long-term
(18 month) study designed to test the hypothesis that intensive weight
loss, either with or without exercise, will reduce knee joint loads and
serum levels of inﬂammatory biomarkers compared to an exercise only
control group in older, overweight and obese adults with symptomatic
knee OA.
Methods: The Intensive Diet and Exercise for Arthritis trial (IDEA) was
a prospective, single-blind, randomized controlled trial that enrolled
454 overweight and obese (BMI ¼ 27-40.5 kg/m2) older (age  55 yrs)
adults with pain and radiographic evidence of tibiofemoral OA (KL ¼
2-3). Participants were randomized to one of three 18-month inter-
ventions: intensive dietary restriction-only (D); intensive dietary
restriction-plus-exercise (D+E); or exercise-only control (E). The
weight loss goal for the two diet groups was  10% of baseline body
weight. The exercise intervention consisted of low to moderate
intensity walking and resistance training 3 d/wk for 1 hr/d. High
speed motion analysis and musculoskeletal modeling were used to
calculate knee joint loads, and fasting serum concentrations of
inﬂammatory biomarkers were measured by enzyme-linked immu-
nosorbent assays. We used an intention-to-treat analysis to compare
differences between groups in changes from baseline (at 6 and 18
month follow-up combined) after adjusting for gender, baseline BMI,
visit (6 and 18 months), and baseline values of the dependent variable
using repeated measures ANCOVA.
Results: Mean baseline descriptive characterisitics of the cohort
included: age, 65.6 yrs.; BMI, 33.6 kg/m2; 72%female; 81%white. A
total of 399 (88%) participants completed the study and returned for
FU18 testing. Mean weight loss was: D, 9.5%; D+E, 11.4%; E, 2.2%.
Mean (SE) IL-6 (pg/mL), the primary inﬂammatory outcome, was
signiﬁcantly changed in the D, -0.43 (0.11) and D+E, -0.36 (0.11)
groups compared to the E, 0.04 (0.11) group (p ¼ 0.005). Similarly,
Leptin (ng/mL) also signiﬁcantly changed in the D, -13 (2) and D+E,
-14 (1) groups relative to the E, -3 (1) group (p < 0.0001). Knee
compressive force (N/step), the primary mechanical outcome, was
signiﬁcantly reduced in the D, -174 (42) and D+E, -51 (40) groups
compared to the E, 154 (41) group (p < 0.0001). Results from the
musculoskeletal model revealed that the differences in knee
compressive forces were associated to signiﬁcant changes (N/step)
in hamstring muscle force (D, -56 (18); D+E, 3 (17); E, 71 (17):
p < 0.0001), gastrocnemius force (D, -43 (6); D+E, -39 (5); E, 12 (5):p < 0.0001), and quadriceps forces (D, -46 (28); D+E, 27 (26); E, 121
(27): p < 0.0001). Changes in the peak internal abductor moment
(Nm), a commonly used surrogate of medial compartment joint
loading, were not different between the groups (D, 0.33 (0.72); D+E,
1.51 (0.69); E, 0.49 (0.70): p ¼0.4), primarily due to heterogeneity in
frontal plane knee alignment among the participants.
Conclusions:This trial shows that intensive weight loss, with or
without exercise, signiﬁcantly impacts both the mechanical and
inﬂammatory OA disease pathways by reducing knee joint compressive
loads and IL-6, respectively. While exercise is effective in improving
clinical outcomes in this population, our data indicate that intensive
weight loss, not exercise, is the non-pharmacologic treatment that
signiﬁcantly impacts both OA disease pathways.
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Purpose: A clear picture about the beneﬁts of repeated courses of
Hyaluronic Acid (HA) on osteoarthritis (OA) is pending to be drawn.
AMELIA (Arthrosis Modifying Effects of Long-term Intra-articular
Adant) is a recently completed multicentre, double-blind, placebo-
controlled clinical trial with a 40 months follow-up to assess the efﬁ-
cacy and tolerability of repeated administration of intra-articular
injections of Adant or placebo in knee osteoarthritis.
Methods: Patients with primary knee osteoarthritis (ACR criteria),
radiological grades II-III according to Kellgren scale and joint space
width >¼2 mm were randomised 1:1 to receive 4 cycles of 5 intra-
articular Adant or placebo (saline) injections each one. The follow up
periods were 6 months long after the ﬁrst and second cycles and 1
year long after the third and fourth ones making total study duration
of 40 months (Figure 1). OMERACT-OARSI 2004 responder criteria
were used for efﬁcacy evaluation. Adverse events were recorded for
safety purposes and monitored until resolution.).
Results: From 446 screened, a total of 306 patients were randomized
and allocated to Adant or placebo. Both groups were homogeneous at
baseline for demographics and OA characteristics (see ARD Nov 2011 for
further details) and a total of 203 patients completed the study
procedures.
At the end of follow-up, signiﬁcantly more patients receiving Adant
responded to treatment in comparison to placebo according to OMER-
ACT-OARSI 2004 criteria (p¼0.004), the number of responders being
22% higher in HA group (RR 1.22; CI 95% 1.07 to 1.41). Signiﬁcant
differences were also found in favour of HA for each individual
component of the OMERACT-OARSI 2004: pain, function and patient
global assessment with p values of 0.025, 0.023 and 0.002 respectively.
Responders to HA injections progressively increased after each treat-
ment cycle (from 71.1% to 80.5%) whereas responders to placebo
remained fairly stable (from 67.8% to 65.8%) providing statistically
signiﬁcant differences between both groups through the study period
(Figure 2). Dropouts due to lack of efﬁcacy were statistically signiﬁcant
lower in HA group (p¼0.026). Paracetamol was consumed by 48% of the
patients and the mean daily dose during the study experienced a 27%
reduction in the HA group compared to baseline versus only a 4% in the
placebo group.
Twenty-two patients (11 per group) experienced a total of 29 related
adverse events, the rate of related adverse events/cycle being 0.029 in
both groups. Most of them were related with the study intervention,
such as local bleeding, pain of mild intensity or allergic reaction and
none of them serious.
Conclusions: AMELIA trial evidence the superiority of Adant to
placebo. Repeated cycles of intra-articular injections of this HA not only
improve knee OA symptoms during the in-between cycle period, but
also exert a marked carry over effect lasting for at least one year after
the last cycle. Adverse reactions were scarce and related to the
administration procedure.
